+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Checkpoint Inhibitors"

From
From
From
From
From
From
CD40 Ligand - Pipeline Review, H2 2019 - Product Thumbnail Image

CD40 Ligand - Pipeline Review, H2 2019

  • Drug Pipelines
  • December 2019
  • 74 Pages
  • Global
From
Cancer Testis Antigen 1 - Pipeline Review, H2 2019 - Product Thumbnail Image

Cancer Testis Antigen 1 - Pipeline Review, H2 2019

  • Drug Pipelines
  • December 2019
  • 76 Pages
  • Global
From
From
From
From
Loading Indicator

The Checkpoint Inhibitors market is a subset of the Oncology Drugs market, which focuses on treatments for cancer. Checkpoint Inhibitors are a type of immunotherapy, which works by blocking certain proteins that act as “checkpoints” in the body’s immune system. By blocking these checkpoints, the body’s immune system is able to recognize and attack cancer cells. This type of therapy has been found to be effective in treating a variety of cancers, including melanoma, non-small cell lung cancer, and bladder cancer. The Checkpoint Inhibitors market is highly competitive, with many companies developing and marketing their own products. Some of the major players in the market include Merck, Bristol-Myers Squibb, Roche, AstraZeneca, and Pfizer. Show Less Read more